A Novel CD147-Targeting Nanobody for Immuno-PET Imaging of Liver Cancer
Journal of Nuclear Medicine · 2026-07 · 67 (7) · 1164-1169
DOI: 10.2967/jnumed.125.271565 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 09.04.2026. Verfasst von Divya M Nambiar und 15 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. Hauptthemen laut MEDLINE: Single-Domain Antibodies, Liver Neoplasms, Positron-Emission Tomography, Basigin. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality, with a 5-y survival rate of approximately 20%. Many patients undergo locoregional therapy, and distinguishing viable tumor from treated necrotic tissue presents a significant clinical challenge with conventional imaging. CD147, a transmembrane glycoprotein overexpressed in approximately 60% of HCC tumors with minimal expression in normal liver, represents a promising target for tumor-selective molecular imaging to address this unmet clinical need. We aimed to develop and characterize a CD147-targeted nanobody-based PET imaging agent compatible with same-day clinical imaging workflows.
Methods
We constructed a phage-display library from a llama immunized with recombinant human CD147. CD147-selective nanobodies were isolated through iterative immunopanning and characterized by enzyme-linked immunosorbent assay, biolayer interferometry, and flow cytometry using isogenic CD147-positive and CD147-knockout liver cancer cell lines. The lead candidate, denoted as DMN1, was radiolabeled with 18F via [18F]FPy pyridine-based prosthetic group conjugation. The radiolabeled nanobody was evaluated in cellular assays and further characterized in vivo using PET/CT imaging and biodistribution studies in subcutaneous and orthotopic murine HCC models.
Results
DMN1 demonstrated low binding affinity to human CD147 (K D = 0.71 ± 0.1 nM, enzyme-linked immunosorbent assay), with specificity confirmed in CD147-positive versus CD147-negative xenografts. [18F]FPy-DMN1 was synthesized with high radiochemical purity (>98%), a molar activity of 3,700-11,100 GBq/μmol, and good serum stability (87% intact in mouse serum at 3 h). In vivo, [18F]FPy-DMN1 showed robust tumor accumulation in CD147-positive (3.82 ± 0.93 %IA/g) versus CD147-negative tumor xenografts (0.21 ± 0.02 %IA/g), with excellent tumor-to-background ratios at 2 h postinjection (tumor-to-blood ratio, 18.7 ± 3.9; tumor-to-muscle ratio, 52.6 ± 22.1). In orthotopic liver tumors, [18F]FPy-DMN1 enabled clear tumor visualization with striking contrast at 3 h postinjection, whereas the control nanobody showed no tumor localization. Conclusion: [18F]FPy-DMN1 is a novel CD147-specific nanobody-based PET imaging agent that demonstrates high target specificity and favorable pharmacokinetics for same-day imaging. Its rapid blood clearance, high tumor-to-background ratios, and successful visualization of orthotopic liver tumors support further development of this agent for imaging and monitoring treatment response in patients with liver cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
- Laboratory of Functional and Molecular Imaging, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland.
- Chemistry and Synthesis Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Rockville, Maryland.
- Laboratory of Molecular Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
- Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; orit.jacobsonweiss@nih.gov freddy.escorcia@nih.gov.
- Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; and.
Zitieren
APA
Nambiar, D. M., Esparza, T. J., Lee, W., Chung, J. Y., Olkowski, C. P., Ghaemi, B., Basuli, F., Shi, J., Baidoo, K. E., Sheehan-Klenk, J., Makala, H., Zhang, H. H., Farber, J. M., Choyke, P. L., Escorcia, F. E., & Jacobson, O. (2026). A Novel CD147-Targeting Nanobody for Immuno-PET Imaging of Liver Cancer. Journal of Nuclear Medicine, 67(7), 1164-1169. https://doi.org/10.2967/jnumed.125.271565
Vancouver
Nambiar DM, Esparza TJ, Lee W, Chung JY, Olkowski CP, Ghaemi B, et al. A Novel CD147-Targeting Nanobody for Immuno-PET Imaging of Liver Cancer. Journal of Nuclear Medicine. 2026;67(7):1164-1169. doi:10.2967/jnumed.125.271565
BibTeX
@article{Nambiar2026,
author = {Nambiar, Divya M and Esparza, Thomas J and Lee, Woonghee and Chung, Joon-Yong and Olkowski, Colleen P and Ghaemi, Behnaz and Basuli, Falguni and Shi, Jianfeng and Baidoo, Kwamena E and Sheehan-Klenk, Julia and Makala, Hima and Zhang, Hongwei H and Farber, Joshua M and Choyke, Peter L and Escorcia, Freddy E and Jacobson, Orit},
title = {A Novel CD147-Targeting Nanobody for Immuno-PET Imaging of Liver Cancer},
journal = {Journal of Nuclear Medicine},
year = {2026},
volume = {67},
number = {7},
pages = {1164--1169},
doi = {10.2967/jnumed.125.271565}
}
EUVIMED